The Funds team of King & Wood Mallesons ("KWM") is advising Ysios Capital ("Ysios") on the launch of its third fund, Ysios BioFund III, with a committed amount of €155 million and a final target siz...
Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million Series A financing, with the par...
Ysios BioFund III will invest in companies that develop disruptive therapeutic products and platform technologies to address clear medical needs following an investment policy similar to its predecess...
€23m has been mainly provided by Cowen Healthcare Investments, an affiliate of Cowen Inc., which joins the existing investor syndicate of LSP and Andera Partners, Forbion, Ysios Capital, Kurma Partn...
Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthca...
Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partner...
The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...
Ysios Capital, a leading biotechnology venture capital firm in Spain, has announced that it has appointed Guillem Laporta as Principal and two new Venture Partners: Lance Berman and Claudia D’August...
H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) have announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck wil...
QIAGEN N.V. has announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular...
The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors. Existing institutional investors (LSP, Kurm...
La inversión de Ysios se enmarca en la segunda ronda de financiación de Babyscripts, en la que ha captado 5,5 millones de dólares en total. Así, 2,5 millones han sido aportados por Ysios y el rest...